The effects of lanthanum carbonate (Fosrenol) and calcium carbonate on renal bone diseaseThe effects of lanthanum carbonate (Fosrenol) and calcium carbonate on renal bone disease
Faculty of Medicine and Health Sciences
Laboratory Experimental Medicine and Pediatrics (LEMP)
Bologna :Monduzzi, 2003[*]2003
Proceedings 9th Asian Pacific Congress of Nephrology (16-20 February 2003)
University of Antwerp
Lanthanum carbonate (Fosrenol(TM), Shire Pharmaceuticals) is a novel treatment for hyperphosphataemia. In this open-label study, we compared the effects of lanthanum carbonate and calcium carbonate on bone in dialysis patients. Paired bone biopsies were taken, at baseline and after 1 year of treatment, in 33 lanthanum- and 30 calcium-treated patients. Serum phosphate levels were well controlled in both groups and lanthanum carbonate was well tolerated. After 1 year of lanthanum carbonate treatment, five of seven patients with low bone turnover at baseline and four of five with hyperparathyroidism developed a more normal bone turnover. Only one; lanthanum patient developed adynamic bone compared with six in the calcium group. Analyses of data so far indicate that lanthanum carbonate does not have any adverse effects on bone.